Valneva’s success stems from the dedication and expertise of approximately 580 employees spanning the whole value chain, from R&D to commercialization.
In 2020, Valneva achieved several major milestones, further enhancing its unique value proposition.
Valneva aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.
Frédéric Jacotot General Counsel and Corporate Secretary
Our commitment to Corporate Governance underpins the trust that our investors, employees and institutions have placed in us.
Valneva has defined long-term responsible business commitments, which reflect global health needs and sit across four key focus areas. Our four pillars are the foundation for our Corporate Social Responsibility approach.